story of the week
Pembrolizumab vs Chemotherapy for Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Lancet Oncol 2022 Apr 12;[EPub Ahead of Print], LA Diaz, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, R Garcia-Carbonero, M Benavides, P Gibbs, C de la Fourchardiere, F Rivera, E Elez, DT Le, T Yoshino, WY Zhong, D Fogelman, P Marinello, T AndreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.